Research

Hormonal

Tirzepatide improves islet cell function and insulin sensitivity more effectively than placebo and GLP-1 receptor agonists, evidenced by greater reductions in fasting insulin, C-peptide, glucagon, and HOMA2-IR.

Tirzepatide helps your body use insulin more efficiently than older GLP-1 drugs. This is shown by larger drops in your fasting insulin and blood sugar resistance markers. This improvement in metabolic health is a key benefit of the medication, alongside weight loss.

GoodSupportsHIGH confidence
The percent reductions in fasting insulin were greater with tirzepatide 10 and 15 mg than with placebo. All doses of tirzepatide caused greater percent reductions in fasting insulin, C‐peptide, and glucagon than GLP‐1RAs. Compared to placebo and GLP‐1RAs, the percent reductions in HOMA2‐IR were greater with all doses of tirzepatide.
A B Kamrul-Hasan et al. · Obesity Science & Practice · 2024

Why this rating

High certainty for enzyme/insulin outcomes, but lower certainty for C-peptide/glucagon due to fewer studies.

Source

Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis

A B Kamrul-Hasan et al. · Obesity Science & Practice · 2024

DOI 10.1002/osp4.70032

Meta-analysis · 17 studiesCited 6×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →